Sign up to save your podcasts
Or
Share FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
FDA approved Avlayah for pediatric Hunter syndrome, delivering enzyme therapy across the blood-brain barrier to address neurologic symptoms and improve developmental outcomes in affected children.
View all episodes
By TheBrief.HealthFDA approved Avlayah for pediatric Hunter syndrome, delivering enzyme therapy across the blood-brain barrier to address neurologic symptoms and improve developmental outcomes in affected children.